Deflazacort 6 Mg Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 6 mg, 18 mg
Reference Brands: Emflaza (USA), Calcort (EU)
Category:
Immune Disorder
Deflazocort is a synthetic corticosteroid used to treat inflammatory and autoimmune conditions, including muscular dystrophy, rheumatoid arthritis, and other chronic inflammatory disorders. It works by suppressing the immune system and reducing inflammation. Available in oral tablet and suspension forms, Deflazocort provides effective anti-inflammatory and immunosuppressive therapy with a relatively favorable side effect profile compared to other corticosteroids.
Deflazacort 6 mg Tablet is available in Tablets
and strengths such as 6 mg, 18 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Deflazacort 6 mg Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Deflazacort 6 mg Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Deflazacort, sold under the brand name Calcort among others, is a synthetic glucocorticoid belonging to the acetonide or O-isopropylidene derivative class. It is primarily used as an anti-inflammatory and immunosuppressive agent, helping to manage a variety of conditions involving inflammation or overactive immune responses. Deflazacort was first patented in 1969 and approved for medical use in 1985. It works by binding to glucocorticoid receptors, modulating gene expression, and reducing the production of inflammatory mediators in the body. The US Food and Drug Administration recognizes deflazacort as a first-in-class therapy for Duchenne Muscular Dystrophy, offering clinical benefits in slowing disease progression and improving muscle function. Its use extends to autoimmune disorders, allergic reactions, and other conditions requiring corticosteroid therapy, providing a balance of efficacy with a generally favorable safety profile compared to some other corticosteroids.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing